News Release
- Avextra’s Supervisory Board welcomes Dr. Stefan Jentzsch, a Partner at Perella Weinberg Partners, a global investment firm. He brings extensive experience in corporate finance, M&A, and investment banking.
- Dr. Jentzsch’s investment banking career includes roles as a Management Board member at Dresdner Bank and HypoVereins Bank, and as a Partner at Goldman Sachs. He is also a Trustee of Kinderhilfestiftung and Chairman of the R.E.S.P.E.K.T. foundation.
- Dr. Jentzsch will support Avextra’s strategic growth and capital raising efforts as the company aims to strengthen its position as a leading European innovator in medicinal cannabis.
Bensheim, Germany, April 3, 2025– Avextra, a prominent European manufacturer of cannabis-based medicines, announced the appointment of Stefan Jentzsch to its Supervisory Board. His decades of financial sector experience and proven success in corporate strategy, M&A, and investment banking will provide valuable expertise as Avextra expands across Europe and advances its clinical program.
Prior to his role as Partner at Perella Weinberg Partners, Mr. Jentzsch was a Management Board Member at Dresdner Bank AG and HypoVereinsbank AG, and a Partner at Goldman, Sachs & Co.
Stefan Jentzsch commented on his appointment: “I am excited to join Avextra’s Supervisory Board at such a pivotal time. Data shows that cannabis-based medicines can improve therapeutic outcomes across various diseases, and Avextra is uniquely positioned to accelerate regulatory approval for well-protected products through its clinical plan. I look forward to supporting the team in driving sustainable growth and delivering value to patients and stakeholders.”
Arno Gerken, Chairman of Avextra’s Supervisory Board, welcomed Mr. Jentzsch, stating: “We are thrilled to have Stefan join Avextra’s Supervisory Board. His expertise in corporate finance, governance, and strategic growth will be instrumental in executing our vision of setting the standard for cannabis-based medicines.”
About Avextra AG
Avextra is a leading vertically integrated medical cannabis and research company in Europe, focused on developing and producing regulator-approved medicines. Founded in 2019 and based in Germany, Avextra collaborates with doctors and pharmacists to develop and produce precisely formulated cannabis-based medicines. The company controls the entire value chain, from cultivation in Portugal to EU-GMP certified extraction and manufacturing in Germany, and operates across continental Europe through an expansive distribution network and strategically developed assets.
Avextra Investor Relations:
For further information, please contact our Investor Relations Team:
Email: investors@avextra.com
Avextra Media Enquiries:
For media enquiries or to set up an interview please contact:
Email: press@avextra.com
Phone: +49 30 408174037
“`